Semaglutide vs Retatrutide
Semaglutide vs Retatrutide: first-gen GLP-1 vs the new triple agonist (GLP-1 + GIP + glucagon). Effect size, side effects, availability.
The verdict
This is the biggest generational gap in the GLP-1 space. Semaglutide is the original single-receptor GLP-1 with years of real-world history and full FDA approval. Retatrutide is the triple agonist with the largest trial weight-loss numbers anyone has shown, but it's still pre-approval. If you want something proven and available, Semaglutide. If you're tracking where the field is heading and the early data holds, Retatrutide is the one to watch.
Semaglutide is the first wave of modern weight-loss drugs, sold as Ozempic and Wegovy. Single-receptor version of Tirzepatide. Slightly less effective and slightly rougher side effects, but well-studied and widely available.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick Semaglutide if beginners to glp-class peptides or users with insurance coverage on wegovy / ozempic.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between Semaglutide and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.